Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy

Yun Sil Lee, Adam Lehar, Suzanne Sebald, Min Liu, Kayleigh A. Swaggart, C. Conover Talbot, Peter Pytel, Elisabeth R. Barton, Elizabeth M. McNally, Se Jin Lee

Research output: Contribution to journalArticle

Abstract

Myostatin is a secreted signaling molecule that normally acts to limit muscle growth. As a result, there is extensive effort directed at developing drugs capable of targetingmyostatin to treat patients with muscle loss. One potential concern with this therapeutic approach in patients with muscle degenerative diseases like muscular dystrophy is that inducing hypertrophy may increase stress on dystrophic fibers, thereby accelerating disease progression. To investigate this possibility, we examined the effect of blocking the myostatin pathway in dysferlin-deficient (Dysf-/-) mice, in which membrane repair is compromised, either by transgenic expression of follistatin in skeletal muscle or by systemic administration of the soluble form of the activin type IIB receptor (ACVR2B/Fc). Here,we showthatmyostatin inhibition by follistatin transgene expression in Dysf-/- mice results in early improvement in histopathology but ultimately exacerbates muscle degeneration; this effect was not observed in dystrophindeficient (mdx) mice, suggesting that accelerated degeneration induced by follistatin transgene expression is specific to mice lacking dysferlin. Dysf-/- mice injected with ACVR2B/Fc showed significant increases in muscle mass and amelioration of fibrotic changes normally seen in 8-month-old Dysf-/- mice. Despite these potentially beneficial effects, ACVR2B/Fc treatment caused increases in serum CK levels in some Dysf-/- mice, indicating possible muscle damage induced by hypertrophy. These findings suggest that depending on the disease context, inducing muscle hypertrophy by myostatin blockade may have detrimental effects, which need to be weighed against the potential gains in muscle growth and decreased fibrosis.

Original languageEnglish (US)
Pages (from-to)5711-5719
Number of pages9
JournalHuman Molecular Genetics
Volume24
Issue number20
DOIs
StatePublished - Jun 5 2015
Externally publishedYes

Fingerprint

Myostatin
Hypertrophy
Muscles
Follistatin
Transgenes
Inbred mdx Mouse
Dysferlinopathy
Muscular Dystrophies
Growth
Disease Progression
Skeletal Muscle
Fibrosis
Membranes

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Lee, Y. S., Lehar, A., Sebald, S., Liu, M., Swaggart, K. A., Conover Talbot, C., ... Lee, S. J. (2015). Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. Human Molecular Genetics, 24(20), 5711-5719. https://doi.org/10.1093/hmg/ddv288

Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. / Lee, Yun Sil; Lehar, Adam; Sebald, Suzanne; Liu, Min; Swaggart, Kayleigh A.; Conover Talbot, C.; Pytel, Peter; Barton, Elisabeth R.; McNally, Elizabeth M.; Lee, Se Jin.

In: Human Molecular Genetics, Vol. 24, No. 20, 05.06.2015, p. 5711-5719.

Research output: Contribution to journalArticle

Lee, YS, Lehar, A, Sebald, S, Liu, M, Swaggart, KA, Conover Talbot, C, Pytel, P, Barton, ER, McNally, EM & Lee, SJ 2015, 'Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy', Human Molecular Genetics, vol. 24, no. 20, pp. 5711-5719. https://doi.org/10.1093/hmg/ddv288
Lee YS, Lehar A, Sebald S, Liu M, Swaggart KA, Conover Talbot C et al. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. Human Molecular Genetics. 2015 Jun 5;24(20):5711-5719. https://doi.org/10.1093/hmg/ddv288
Lee, Yun Sil ; Lehar, Adam ; Sebald, Suzanne ; Liu, Min ; Swaggart, Kayleigh A. ; Conover Talbot, C. ; Pytel, Peter ; Barton, Elisabeth R. ; McNally, Elizabeth M. ; Lee, Se Jin. / Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 20. pp. 5711-5719.
@article{92ab4826d84747a1990a053c2963b27c,
title = "Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy",
abstract = "Myostatin is a secreted signaling molecule that normally acts to limit muscle growth. As a result, there is extensive effort directed at developing drugs capable of targetingmyostatin to treat patients with muscle loss. One potential concern with this therapeutic approach in patients with muscle degenerative diseases like muscular dystrophy is that inducing hypertrophy may increase stress on dystrophic fibers, thereby accelerating disease progression. To investigate this possibility, we examined the effect of blocking the myostatin pathway in dysferlin-deficient (Dysf-/-) mice, in which membrane repair is compromised, either by transgenic expression of follistatin in skeletal muscle or by systemic administration of the soluble form of the activin type IIB receptor (ACVR2B/Fc). Here,we showthatmyostatin inhibition by follistatin transgene expression in Dysf-/- mice results in early improvement in histopathology but ultimately exacerbates muscle degeneration; this effect was not observed in dystrophindeficient (mdx) mice, suggesting that accelerated degeneration induced by follistatin transgene expression is specific to mice lacking dysferlin. Dysf-/- mice injected with ACVR2B/Fc showed significant increases in muscle mass and amelioration of fibrotic changes normally seen in 8-month-old Dysf-/- mice. Despite these potentially beneficial effects, ACVR2B/Fc treatment caused increases in serum CK levels in some Dysf-/- mice, indicating possible muscle damage induced by hypertrophy. These findings suggest that depending on the disease context, inducing muscle hypertrophy by myostatin blockade may have detrimental effects, which need to be weighed against the potential gains in muscle growth and decreased fibrosis.",
author = "Lee, {Yun Sil} and Adam Lehar and Suzanne Sebald and Min Liu and Swaggart, {Kayleigh A.} and {Conover Talbot}, C. and Peter Pytel and Barton, {Elisabeth R.} and McNally, {Elizabeth M.} and Lee, {Se Jin}",
year = "2015",
month = "6",
day = "5",
doi = "10.1093/hmg/ddv288",
language = "English (US)",
volume = "24",
pages = "5711--5719",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "20",

}

TY - JOUR

T1 - Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy

AU - Lee, Yun Sil

AU - Lehar, Adam

AU - Sebald, Suzanne

AU - Liu, Min

AU - Swaggart, Kayleigh A.

AU - Conover Talbot, C.

AU - Pytel, Peter

AU - Barton, Elisabeth R.

AU - McNally, Elizabeth M.

AU - Lee, Se Jin

PY - 2015/6/5

Y1 - 2015/6/5

N2 - Myostatin is a secreted signaling molecule that normally acts to limit muscle growth. As a result, there is extensive effort directed at developing drugs capable of targetingmyostatin to treat patients with muscle loss. One potential concern with this therapeutic approach in patients with muscle degenerative diseases like muscular dystrophy is that inducing hypertrophy may increase stress on dystrophic fibers, thereby accelerating disease progression. To investigate this possibility, we examined the effect of blocking the myostatin pathway in dysferlin-deficient (Dysf-/-) mice, in which membrane repair is compromised, either by transgenic expression of follistatin in skeletal muscle or by systemic administration of the soluble form of the activin type IIB receptor (ACVR2B/Fc). Here,we showthatmyostatin inhibition by follistatin transgene expression in Dysf-/- mice results in early improvement in histopathology but ultimately exacerbates muscle degeneration; this effect was not observed in dystrophindeficient (mdx) mice, suggesting that accelerated degeneration induced by follistatin transgene expression is specific to mice lacking dysferlin. Dysf-/- mice injected with ACVR2B/Fc showed significant increases in muscle mass and amelioration of fibrotic changes normally seen in 8-month-old Dysf-/- mice. Despite these potentially beneficial effects, ACVR2B/Fc treatment caused increases in serum CK levels in some Dysf-/- mice, indicating possible muscle damage induced by hypertrophy. These findings suggest that depending on the disease context, inducing muscle hypertrophy by myostatin blockade may have detrimental effects, which need to be weighed against the potential gains in muscle growth and decreased fibrosis.

AB - Myostatin is a secreted signaling molecule that normally acts to limit muscle growth. As a result, there is extensive effort directed at developing drugs capable of targetingmyostatin to treat patients with muscle loss. One potential concern with this therapeutic approach in patients with muscle degenerative diseases like muscular dystrophy is that inducing hypertrophy may increase stress on dystrophic fibers, thereby accelerating disease progression. To investigate this possibility, we examined the effect of blocking the myostatin pathway in dysferlin-deficient (Dysf-/-) mice, in which membrane repair is compromised, either by transgenic expression of follistatin in skeletal muscle or by systemic administration of the soluble form of the activin type IIB receptor (ACVR2B/Fc). Here,we showthatmyostatin inhibition by follistatin transgene expression in Dysf-/- mice results in early improvement in histopathology but ultimately exacerbates muscle degeneration; this effect was not observed in dystrophindeficient (mdx) mice, suggesting that accelerated degeneration induced by follistatin transgene expression is specific to mice lacking dysferlin. Dysf-/- mice injected with ACVR2B/Fc showed significant increases in muscle mass and amelioration of fibrotic changes normally seen in 8-month-old Dysf-/- mice. Despite these potentially beneficial effects, ACVR2B/Fc treatment caused increases in serum CK levels in some Dysf-/- mice, indicating possible muscle damage induced by hypertrophy. These findings suggest that depending on the disease context, inducing muscle hypertrophy by myostatin blockade may have detrimental effects, which need to be weighed against the potential gains in muscle growth and decreased fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84943804865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943804865&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddv288

DO - 10.1093/hmg/ddv288

M3 - Article

C2 - 26206886

AN - SCOPUS:84943804865

VL - 24

SP - 5711

EP - 5719

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 20

ER -